De samfundsøkonomiske konsekvenser ved ... - Gigtforeningen

22. Lanes SF et al. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a
managed care setting: the importance of drug and surgery costs. Arthritis & Rheumatism 1997;
40(8):1475-1481.
23. Lapsley HM et al. Living with osteoarthritis: Patient expenditures, health status, and social impact.
Arthritis & Rheumatism 2001 45(3): 301-306.
24. Lee DW, Meyer JW, Clouse J. Implications of controlling for co-morbid conditions in cost-of-illness
estimates: a case study of osteoarthritis from a managed care system perspective. Value-Health,
2001 Jul-Aug: 4(4) 239-24.
25. Levy E, Ferme A, Perocheau D, Bono I. Les coûts socio-économiques de l'arthrose en France. Rev.
Rhum 1993, 60:635-675.
26. Lord J et al. Economic evaluation of a primary care-based education programme for patients with
osteoarthritis of the knee. Health Technology Assessment 1999; Vol. 3(23):55.
27. Lægemiddelstyrelsen: "Salg i den primære sektor 2001", (inkluderer såvel håndkøbs- som receptmedicin,
og salg til den primære sektor), udleveret fra Lægemiddelsstyrelsen på basis af Lægemiddelstatistikken
2001.
28. MacLean CH et al. Cost attributable to osteoarthritis. Journal of Rheumatology 1998;25(11):2213-
2218.
29. Maetzel A, Krahn M, Naglie G. The cost-effectiveness of celecoxib and rofecoxib in patients with
osteoarthritis or rheumatoid arthritis. Canadian Coordinating Office for Health Technology Assessment
(CCOHTA) 2002 (Technology Report No. 23):39.
30. March LM, Bachmeier CJ. Economics of osteoarthritis: a global perspective. Bailliere’s Clinical
Rheumatology 1997 Nov; 11(4):817-34.
31. Mazzuca SA et al. Reduced utilization and cost of primary care clinic visits resulting from self-care
education for patients with osteoarthritis of the knee. Arthritis & Rheumatism 1999;42(6):1267-
1273.
32. McCabe CJ et al. Choice of NSAID and management strategy in rheumatoid arhtritis and osteoarthritis:
the impact on costs and outcomes in the UK. Pharmacoeconomics 1998;14(2):191-199.
33. Moore RA, Phillips CJ, Pellissier JM, Kong SX. Health economic comparisons of rofecoxib versus
conventional non-stereoidal anti-inflammatory drugs for osteoarthritis in the United Kingdom.
Journal of Medical Economics 2001;4:1-17.
34. NASTRA, det nationale strategiudvalg for sundhedsvidenskab: Forslag til en national strategi for
sundhedsvidenskab. Forskningsministeriet, Betænkning nr. 1284, januar 1995.
35. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community
burden and current use of primary health care. Ann. Rheum, Dis 2001;60:91-97.
36. Pellissier JM et al. Economic evaluation of rofecoxib versus non-selective non-steroidal antiinflammatory
drugs for the treatment of osteoarthritis. Clinical Therapeutics 2001:23(7):1061-
1079.
37. Peloso PM, Scheiman JM. The economic implications of cyclooxygenase-2-specific inhibitors.
American Journal of Medicine 2001; Feb 19: 110 Suppl 3A: 50S-4S.
38. Ramsey SD et al. Use of alternative therapies by older adults with osteoarthritis. Arthritis & Rheumatism
2001;45(3):222-227.
39. Rasmussen PH, Nielsen CV. Førtidspensionisters udnyttelse af resterhvervsevnen. Ugeskr Læger
2003;165(13):1335-1338.
40. Rasmussen SR. De samfundsøkonomiske omkostninger ved tobaksrygning. Master of Public Health,
1998, Århus Universitet, udgivelse nr. 9.
41. Rodríguez LA, G Hernández-Díaz S. The risk of upper gastrointestinal complications associated
with non-steroidal anti-inflammatory drugs, glucocorticoids, acetaminophen and combinations of
these agents. Review 2001 BioMed Central Ltd.
48 | DE SAMFUNDSØKONOMISKE KONSEKVENSER VED BEHANDLING AF SLIDGIGT I DANMARK